Open-Label study of bevacizumab (Avastin�) and taxane monotherapy for the first-line treatment of patients with advanced triple-negative breast cancer
Read time: 1 mins
Last updated:1st Oct 2009
Tolerability and safety profile of bevacizumab when combined with weekly paclitaxel as first line treatment of metastatic triple negative breast cancer.
|Study start date||2009-10-01|